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Abstract
Background: Statins have recently been highlighted for their pleiotropic actions distinct from cholesterol-lowering effects.
Despite this interest, it is currently unknown whether statin therapy inhibits peritoneal dialysis (PD)-related epithelial-
mesenchymal transition (EMT).
Methods: In vitro, human peritoneal mesothelial cells (HPMCs) were exposed to 5.6 mM glucose (NG) or 100 mM glucose
(HG) with or without simvastatin (1 mM). In vivo, PD catheters were inserted into 32 Sprague-Dawley rats, and saline (C,
n = 16) or 4.25% peritoneal dialysis fluid (PDF) (PD, n = 16) was infused for 4 weeks. Eight rats from each group were treated
with 5 mg/kg/day of simvastatin intraperitoneally. Changes in the protein expression of EMT markers such as E-cadherin, a-
SMA, Snail, and fibronectin in HPMCs and the peritoneum were evaluated by Western blot analysis and
immunofluorescence or immunohistochemical staining. We also explored whether activation of the mevalonate pathway
and its downstream small GTPases were involved in dialysis-related peritoneal EMT and could be inhibited by statin
treatment.
Results: Compared to NG cells, E-cadherin expression was significantly decreased, while a-SMA, Snail, and fibronectin
expression were significantly increased in HPMCs exposed to HG, and these changes were abrogated by simvastatin (p,
0.05). In addition, the cobblestone-like appearance of normal HPMCs was converted into a fibroblast-like morphology after
HG treatment, which was reversed by simvastatin. These EMT-like changes were also observed in HPMCs treated with
geranyl-geranyl pyrophosphate (5 mM). HG significantly increased the protein expression of RhoA and Rac1 in the
membrane fractions, and these increases were ameliorated by simvastatin (p,0.05). In PD rats, E-cadherin in the
peritoneum was significantly decreased, whereas a-SMA, Snail, and fibronectin expression were significantly increased (p,
0.05) compared to C rats. The thickness of the mesothelial layer in the peritoneum were also significantly greater in PD rats
than in C rats (p,0.05). These changes of the peritoneum in PD rats were significantly attenuated by simvastatin.
Conclusion: This study demonstrated that PD-related EMT was mediated via the mevalonate pathway, and statin treatment
inhibited the EMT changes in HG-treated HPMCs and PDF-stimulated PD rats. These findings suggest that statins may be a
promising therapeutic strategy for preservation of peritoneal membrane integrity in long-term PD patients.
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Introduction
Even though peritoneal dialysis (PD) is generally accepted as an
established modality for the management of patients with end-
stage renal disease (ESRD), a concern about peritoneal membrane
failure has consistently been raised in long-term PD. Many factors
have been demonstrated to be involved in the development of
peritoneal dysfunction. In particular, the nonphysiologic nature of
PD solutions—high concentrations of glucose and lactate, low pH,
and glucose degradation products—is a major factor responsible
for deleterious effects on the peritoneal membrane [1,2]. These
components also induce chronic inflammation in the peritoneal
cavity, which is often exacerbated by recurrent episodes of
peritonitis and consequently leads to structural and functional
alterations of the peritoneal membrane [3].
PLOS ONE | www.plosone.org 1 October 2014 | Volume 9 | Issue 10 | e109628
Peritoneal fibrosis (PF) is the ultimate form of peritoneal
damage. It is characterized by the loss of the peritoneal mesothelial
cell (PMC) monolayer, submesothelial fibrosis, angiogenesis, and
hyalinizing vasculopathy [3–6]. In the past, resident stromal
fibroblasts and inflammatory cells had been considered to be the
main cells responsible for PF [7,8]. Recently, however, PMCs have
emerged as an active player in the alteration of the peritoneal
membrane. After PD initiation, PMCs progressively lose their
epithelial characteristics and acquire a myofibroblast-like pheno-
type through the process of epithelial-mesenchymal transition
(EMT) [5]. EMT is a normal physiologic process during embryo
implantation, embryogenesis, or organ development, but it is also
involved in various pathologic processes, including cancer
metastasis and fibrotic disorders [7]. Indeed, EMT enables PMCs
to gain migratory and invasive capacities, thus they can intrude
into the subepithelial stroma and produce extracellular matrix
(ECM) components such as fibronectin and collagen, which
ultimately leads to PF [8].
Recently, numerous aspects of 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG-CoA) reductase inhibitors, or statins, have
been highlighted due to their pleiotropic effects aside from their
lipid-lowering property [9–11]. Of note, one of the key actions of
statins is inhibition of the downstream products of the mevalonate
pathway such as farnesyl pyrophosphate (FPP) and geranyl-
geranyl pyrophosphate (GGPP) [12]. As a result, isoprenylation of
small RhoGTPases and Ras, the final products of this pathway, is
inhibited [13–15]. Interestingly, previous studies have found that
activation of small RhoGTPases such as RhoA, Rac1, and Cdc42
plays a key role in the process of EMT implicated in diverse renal
diseases [16–19]. In addition, a recent study by Zhang et al. [20]
showed that the RhoA/ROCK signaling pathway mediated EMT
in rat PMCs in response to transforming growth factor (TGF)-b1.
These findings suggest that statins may reverse EMT-like changes
through the inhibition of isoprenylation of small RhoGTPases.
However, to our knowledge, this assumption has not yet been
tested. In this study, therefore, we investigated the effect of statins
on PD-related EMT both in vitro and in vivo.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol for all animal experiments was approved by the Ethics
Committee and the Institutional Animal Care and Use Committee
of Yonsei University College of Medicine.
Human omental tissue was obtained from patients who
underwent elective abdominal surgery. For the use of omental
tissue, we obtained written informed consent from these patients
and received approval from the Institutional Review Board of our
institution.
Isolation of human PMCs (HPMCs)
HPMCs were isolated according to the method described by
Stylianou et al [21]. Briefly, a piece of human omentum was
washed three times with sterile phosphate-buffered saline (PBS)
and incubated in a 0.05% trypsin-0.02% ethylenediaminetetra-
acetic acid (EDTA) solution for 20 min at 37uC with continuous
shaking. After incubation, the suspension containing free HPMCs
was centrifuged at 1006g for 10 min at 4uC. The cell pellet was
then washed once and re-suspended in M199 medium supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml penicillin,
100 mg/ml streptomycin, and 26 mM NaHCO3, and seeded onto
culture dishes. The cells were grown in the same medium at 37uC
in humidified 5% CO2 in air, and the medium was changed 24 hr
after seeding, and then every 3 days.
HPMCs experiments
Subconfluent HPMCs were serum-restricted for 24 hr, and the
medium was then changed to serum-free M199 medium
containing normal glucose (5.6 mM, NG), NG + mannitol
(94.4 mM, NG+M), NG + simvastatin (1 mM) (Sigma Chemical
Co., St Louis, MO, USA), or high glucose (100 mM, HG) with or
without simvastatin (1 mM). The dose of simvastatin used in the
experiments was determined using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) cell viability assay and
trypan blue exclusion. To explore whether isoprenoids of the
mevalonate pathway were involved in peritoneal EMT, HPMCs
were treated with NG+GGPP (5 mM) (Sigma Chemical Co.).
HPMCs exposed to HG were also treated with Rho/ROCK
inhibitor (Y27632, 1 mM) (Sigma Chemical Co.) or Rac inhibitor
(EHT1864, 1 mM) (R&D Systems, Minneapolis, MN, USA). At
72 hr after the media change, cells were harvested.
Evaluation of small GTPase activation. To examine the
activation of small GTPases, membrane and cytosol proteins were
prepared separately and the expression of RhoA and Rac1 were
determined in each fraction by Western blotting. Briefly, HPMCs
treated as above were washed with cold PBS and lysed by freeze-
thawing in ice-cold lysis buffer containing 50 mM HEPES
(pH 7.4), 5 mM NaCl, 1 mM MgCl2, 2 mM EDTA, 1 mM
dithiothreitol, 10 mM sodium fluoride, 1 mM phenylmethylsulfo-
nyl fluoride, 10 mg/ml aprotonin, and 10 mg/ml leupeptin (Sigma
Figure 1. MTT (A) and tryphan blue (B) assay for cell viability.
HPMCs were incubated for 72 hr with 5.6 mM glucose (NG), NG+
mannitol (94.4 mM, NG+M), high glucose (100 mM, HG), or HG+0.1 mM,
1 mM, or 10 mM simvastatin (HG + statin). Cell viability was maintained
at up to 1 mM simvastatin, but was decreased by 20% at 10 mM. *; p,
0.05 vs. other groups.
doi:10.1371/journal.pone.0109628.g001
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Chemical Co.). The homogenates were centrifuged at 4uC and
100,0006g for 30 min and the resulting supernatant (cytosolic
fraction) was collected. The pellets were then homogenized in the
same lysis buffer containing 2% Triton X-114 and centrifuged at
8006g for 10 min at 4uC, and the supernatant was collected. This
supernatant was referred to as the membrane fraction. The
activity of Rho-kinase was determined by using the colorimetric
G-LISA RhoA activation assay biochemical kit (Cytoskeleton,
Denver, CO, USA) according to the manufacturer’s protocol as
previously described [22].
Animal studies
Peritoneal access ports were inserted in 32 male Sprague-
Dawley rats weighing 250–280 g, and 2 ml of saline with 1 IU/ml
heparin was instilled intraperitoneally until wound healing. One
week after surgery, 16 rats received a daily (once per day) 20 ml of
saline instillation and 16 rats were instilled daily with 20 ml of
4.25% peritoneal dialysis fluid (PDF, Dianeal, Baxter Healthcare
Ltd., Singapore) for 4 weeks. Eight rats from each group were
treated with simvastatin (5 mg/kg per day) intraperitoneally, while
8 rats in each group were left untreated (control). Simvastatin dose
was determined based on the previous studies [23,24]. After 4
weeks of PD, the abdomen was opened by a midline incision and
Figure 2. Effects of simvastatin on EMT and fibronectin expression in HPMCs. (A) HPMCs were incubated for 72 hr with 5.6 mM glucose
(NG), NG + mannitol (94.4 mM, NG+M), NG+1 mM simvastatin (NG + statin), high glucose (100 mM, HG), or HG+1 mM simvastatin (HG + statin) (A
representative of five Western blots). E-cadherin protein expression was significantly lower, while the protein expression of Snail, a-SMA, and
fibronectin were significantly higher in HG-stimulated HPMCs compared to NG cells, and these changes were significantly attenuated by simvastatin.
*; p,0.05 vs. NG, {; p,0.05 vs. HG. (B) Compared to NG cells, HPMCs cultured under HG medium showed a weak staining of E-cadherin, a strong
signal intensity of a-SMA, and increased nuclear translocation of Snail, all of which were ameliorated by the administration of simvastatin (6400).
doi:10.1371/journal.pone.0109628.g002
Figure 3. Morphologic changes under an inverted phase-contrast microscope in HPMCs exposed to 5.6 mM glucose (NG), NG +
mannitol (94.4 mM, NG+M), NG+1 mM simvastatin (NG + statin), high glucose (100 mM, HG), or HG+1 mM simvastatin (HG + statin).
The cobblestone-like appearance of HPMCs was converted into a fibroblast-like morphology 72 hr after HG treatment, which was reversed by
simvastatin (640).
doi:10.1371/journal.pone.0109628.g003
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the entire anterior abdominal wall was removed at the contralat-
eral side to the tip of the implanted catheter. One fifth of the whole
tissue adjacent to the liver was fixed in 10% neutral-buffered
formalin for pathologic examination, while the parietal peritone-
um dissected from the major part of the tissue was washed in ice-
cold PBS, snap-frozen in liquid nitrogen, pulverized with a mortar
and pestle while frozen, and suspended in SDS sample buffer [2%
SDS, 10 mM Tris-HCl, pH 6.8, 10% (vol/vol) glycerol]. After
centrifugation at 16,0006g for 15 min at 4uC, the supernatant was
kept at 280uC until use.
Western blot analysis
The protein expression of E-cadherin (BD Biosciences, San
Jose, CA, USA), Snail (Abcam, Cambridge, UK), a-SMA (Sigma
Chemical Co.), fibronectin (DAKO, Glostrup, Denmark), RhoA
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and
Rac1 (Abcam) in HPMCs and peritoneal tissue was evaluated by
Western blot as previously described [25]. The band densities were
measured using Image J software v1.60 (National Institutes of
Health Image software, Bethesda, Maryland, USA; online at
http://rsbweb.nih.gov/ij), and the densitometric intensity corre-
sponding to each band was normalized with a/b tubulin
expression. The changes in the optical densities of bands from
the treated groups relative to NG cells or the peritoneum of
control rats were used in the analysis.
Immunofluorescence staining
HPMCs grown on chamber slides were fixed in 4% parafor-
maldehyde for 10 min at 4uC, washed three times with PBS, and
incubated with 1% BSA for 20 min at room temperature. For
Figure 4. RhoA1 and Rac1 protein expression in the membrane and cytosol fractions of HPMCs exposed to 5.6 mM glucose (NG),
NG + mannitol (94.4 mM, NG+M), NG+1 mM simvastatin (NG + statin), high glucose (100 mM, HG), or HG+1 mM simvastatin (HG +
statin). (A) The protein expression of RhoA and Rac1 were significantly increased in the membrane fraction of HG-stimulated HPMCs compared to
NG cells, and simvastatin significantly attenuated the increases in RhoA and Rac1 expression in the membrane fraction of HPMCs exposed to HG. *;
p,0.05 vs. NG, {; p,0.05 vs. HG. (B) An immunofluorescence study revealed that HG provoked the translocation of RhoA and Rac1 from the cytosol
to the membrane fraction, and simvastatin treatment inhibited this translocation of RhoA and Rac1 induced by HG (640). (C) The levels of Rho kinase
were significantly increased in HG-treated HPMCs than in NG cells, and these changes were significantly abrogated by simvastatin. *; p,0.05 vs. NG, {;
p,0.05 vs. HG.
doi:10.1371/journal.pone.0109628.g004
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immunofluorescence staining, primary polyclonal antibodies to E-
cadherin, Snail, a-SMA, RhoA, and Rac1 were diluted in 1:100
with antibody diluent (DAKO) and were applied for 3 hr at room
temperature. After washing with PBS, Cy3 (red)- or Cy2 (green)-
conjugated anti-rabbit IgG antibody (Research Diagnostics, Inc.,
Flanders, NJ, USA) was added for 60 min.
Immunohistochemical and Masson’s trichrome staining
The peritoneum samples were fixed in 10% neutral-buffered
formalin, processed in the standard manner, and 5 mm-thick
sections of paraffin-embedded tissues were utilized for immuno-
histochemical staining. Slides were deparaffinized, hydrated in
ethyl alcohol, and washed in tap water. Antigen retrieval was
carried out in 10 mM sodium citrate buffer for 20 min using a
Black & Decker vegetable steamer. Primary antibodies for E-
cadherin, Snail, a-SMA, and fibronectin were diluted to the
appropriate concentrations with 2% casein in bovine serum
albumin (BSA), and then were added to the slides with an
overnight incubation at 4uC. After washing, a secondary antibody
was added for 20 min, and the slides were washed and incubated
with a tertiary PAP complex for 20 min. Diaminobenzidine was
added for 2 min and the slides were counterstained with
hematoxylin. A semi-quantitative score of staining intensity was
determined by examining at least 5 fields of the peritoneum in
each section under 6400 magnification and by digital image
analysis (MetaMorph version 4.6r5, Universal Imaging Corp.,
Downingtown, PA, USA). For Masson’s trichrome staining, 5 mm-
thick sections of paraffin-embedded tissues were deparaffinized,
hydrated in ethyl alcohol, washed in tap water, and re-fixed in
Bouin’s solution at 56uC for 1 hr. After washing in running tap
water for 10 min and staining with Weigert’s iron hematoxylin
working solution for 10 min, the sections were stained with
Biebrich scarlet-acid fuchsin solution for 15 min, followed by a 10-
min wash. The slides were then differentiated in phosphomolyb-
dic-phosphotungstic acid solution for 15 min, transferred to
aniline blue solution and stained for 10 min, and were reacted
with 1% acetic acid solution for 5 min. The thickness of the
peritoneum, which was defined as the tissue between the
mesothelial surface and the underlying muscle or parenchyma,
was assessed as previously described [26]. Briefly, the maximal
thickness of the peritoneum was measured in three Masson’s
trichrome-stained tissue sections per rat and five fields, the center
of which included the area of maximal thickness, and were
examined under6400 magnification. Areas and perimeter lengths
of the peritoneum were obtained from drawn outlines and the
average thickness was calculated from rectangular approximation
based on the values for area and perimeter in each field of view.
Statistical analysis
All values are expressed as means6 standard errors of the mean
(SEM). Statistical analyses were performed using the statistical
package SPSS for Windows Ver. 11.0 (SPSS, Inc., Chicago, IL,
USA). Results were analyzed using one-way ANOVA with a post
hoc Bonferonni’s test for multiple comparisons. P-values ,0.05
were considered statistically significant.
Figure 5. The protein expression of EMT markers and fibronectin in HPMCs. HPMCs were incubated with 5.6 mM glucose (NG) and NG+
5 mM GGPP (NG+GGPP) for 72 hr. (A) GGPP treatment significantly decreased E-cadherin expression and significantly increased the protein expression
of Snail, a-SMA, and fibronectin in HPMCs (A representative of five Western blots). *; p,0.05 vs. NG. (B) The protein expression of RhoA and Rac1 were
significantly increased in the membrane fraction of HPMCs exposed to GGPP. *; p,0.05 vs. NG.
doi:10.1371/journal.pone.0109628.g005
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Results
Effects of simvastatin on EMT and fibronectin expression
in HPMCs
As shown in Figure 1, the MTT assay demonstrated that
HPMCs remained viable at up to 1 mM of simvastatin, but the
viability was decreased by 20% at 10 mM. The viability was also
assessed by trypan blue exclusion, in which all groups demon-
strated.95% viability, suggesting no differences between control
and simvastatin (1 mM)-treated groups. Therefore, the dose of
1 mM was used for the experiments. To evaluate the effects of
statins on EMT in vitro, HPMCs were incubated for 72 hr with
NG, NG+M, NG+simvastatin, or HG with or without simvastatin.
E-cadherin protein expression was significantly lower, while the
protein expression of Snail, a-SMA, and fibronectin were
significantly higher in HG-stimulated HPMCs compared to NG
cells (P,0.05) (Fig. 2A). Furthermore, the changes in HPMCs
exposed to HG were significantly abrogated by simvastatin
treatment (P,0.05) (Fig. 2A). These findings were corroborated
by the immunofluorescence analysis. HPMCs cultured under HG
medium showed a weak staining of E-cadherin, a strong signal
intensity of a-SMA, and increased nuclear translocation of Snail,
all of which were ameliorated by the administration of simvastatin
(Fig. 2B). On the other hand, mannitol used as an osmotic control
had no effect on EMT and fibronectin expression in HPMCs. In
addition, the expression of EMT markers and fibronectin in NG
cells was not affected by simvastatin.
Moreover, we observed the morphologic changes of HPMCs
under an inverted phase-contrast microscope. The cobblestone-
like appearance of HPMCs was converted into a fibroblast-like
morphology after HG treatment, which was reversed by
simvastatin (Fig. 3).
Activation of small GTPases such as RhoA and Rac1 in
HPMCs. Posttranslational modification of Rho proteins by
geranyl-geranlyation is essential for their membrane location and
activity. Thus, the assessment of these proteins in the membrane
fraction of the cells can reflect their degree of prenylation through
the mevalonate pathway [27,28]. Since inhibiting isoprenylation of
the mevalonate pathway products was the main mechanism of
statins, the membrane-associated protein expression of RhoA and
Rac1 was evaluated in HPMCs by Western blot analysis after
separation of the membrane and cytosol fractions. Compared to
NG cells, the protein expression of RhoA and Rac1 were
significantly increased in the membrane fraction of HG-stimulated
HPMCs (P,0.05), and simvastatin significantly abrogated the
increases in RhoA and Rac1 expression in the membrane fraction
of HPMCs exposed to HG (P,0.05) (Fig. 4A). Furthermore, the
immunofluorescence study revealed that HG provoked the
translocation of RhoA and Rac1 from the cytosol to the
membrane fraction, and simvastatin treatment inhibited this
translocation of RhoA and Rac1 induced by HG (Fig. 4B). In
addition, the levels of Rho kinase were significantly increased in
HG-treated HPMCs than in NG cells (P,0.05), and these changes
were significantly ameliorated by simvastatin (P,0.05) (Fig. 4C).
Figure 6. The protein expression of EMT markers and fibronectin in HPMCs exposed to 5.6 mM glucose (NG), NG with 1 mM Y27632
(Rho/ROCK inhibitor) (NG+Y27632), NG with 1 mM EHT1864 (Rac inhibitor) (NG+EHT1864), high glucose (100 mM, HG), HG with
1 mM Y27632 (HG+Y27632), or HG with 1 mM EHT1864 (HG+EHT1864). The administration of Y27632 and EHT1864 significantly attenuated
the changes in EMT markers and fibronectin expression in HPMCs cultured under HG medium. *; p,0.05 vs. NG, {; p,0.05 vs. HG, `; p,0.05 vs. HG.
doi:10.1371/journal.pone.0109628.g006
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Involvement of isoprenoids of the mevalonate pathway
in EMT of HPMCs
To evaluate whether isoprenoids of the mevalonate pathway
were involved in peritoneal EMT, HPMCs were incubated with
5 mM GGPP for 72 hr. The administration of GGPP significantly
decreased E-cadherin protein expression and significantly in-
creased the protein expression of Snail, a-SMA, and fibronectin in
HPMCs (P,0.05) (Fig. 5A). The protein expression of RhoA and
Rac1 were also significantly increased in the membrane fraction of
HPMCs exposed to GGPP (P,0.05) (Fig. 5B).
Effect of small GTPase inhibitors on EMT and fibronectin
expression in HPMCs
Rho/ROCK inhibitor (Y27632) and Rac inhibitor (EHT1864)
were added to HG-stimulated HPMCs, and the changes in EMT
markers and fibronectin expression were determined. The
administration of these two small GTPase inhibitors significantly
ameliorated the changes in EMT markers and fibronectin
expression in HPMCs cultured under HG medium (P,0.05)
(Fig. 6).
Effects of simvastatin on peritoneal EMT and ECM
accumulation in a PD rat model
Finally, the effects of simvastatin on peritoneal EMT and ECM
accumulation were explored in a PD rat model. E-cadherin
protein expression was significantly lower, while Snail, a-SMA,
and fibronectin protein expression were significantly higher in rats
treated with 4.25% PDF compared to control rats (P,0.01), and
these changes were significantly abrogated by simvastatin treat-
ment (P,0.05) (Fig. 7). Immunohistochemical staining of the
peritoneum also revealed that EMT markers and fibronectin
protein expression were significantly higher in rats treated with
4.25% PDF relative to control rats, and simvastatin significantly
attenuated EMT and ECM accumulation in PD rats (Fig. 8).
Moreover, Masson’s trichrome staining found that the subme-
sothelial layer was significantly thicker and peritoneal fibrosis was
more extensive in PD rats with 4.25% PDF than control rats, and
these changes were significantly abrogated by simvastatin treat-
ment (Fig. 9).
Discussion
PF is one of the most serious complications of long-term PD,
leading to membrane failure. Even though resident peritoneal
fibroblasts and infiltrating inflammatory cells have been consid-
ered to play a key role in the development PF, EMT of PMCs has
recently been highlighted as another potential mechanism
responsible for PF [5–8]. This study shows for the first time that
statin treatment abrogates PD-related EMT of HPMCs and ECM
accumulation in a PD rat model. In addition, we demonstrate that
these beneficial effects of statin are mediated, at least in part, by
inhibiting isoprenylation of small RhoGTPases such as RhoA and
Rac1.
Besides a physiologic role of EMT in embryogenesis or organ
development, it also plays a pathologic role in cancer metastasis
and fibrotic disorders.7 A number of recent studies have found that
PMCs also undergo EMT during PD [5,29–31]. In particular,
Yanez-Mo et al. [5] showed that PMCs undergo a transition from
Figure 7. The protein expression of EMT markers and ECM in the peritoneum of control (C), C+ simvastatin (C + statin), 4.25% PDF
instillation (PD), or 4.25% PDF + simvastatin (PD + statin) rats. E-cadherin protein expression was significantly lower, while Snail, a-SMA, and
fibronectin protein expression were significantly higher in rats treated with 4.25% PDF compared to control rats, and these changes were significantly
ameliorated by simvastatin. *; p,0.05 vs. C, {; p,0.05 vs. PD.
doi:10.1371/journal.pone.0109628.g007
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an epithelial phenotype to a mesenchymal phenotype soon after
PD is initiated and this process is accompanied by a decrease in
the expression of cytokeratins and E-cadherin, suggesting that
these cells indeed acquire structural changes during PD. Consis-
tent with these findings, in the present study, E-cadherin
expression was significantly decreased, while Snail, a-SMA, and
fibronectin expression was significantly increased in HPMCs
exposed to HG and in the peritoneum of rats instilled with 4.25%
PDF. Furthermore, the cobblestone-like appearance of normal
HPMCs was converted into a fibroblast-like morphology after HG
treatment. These findings support previous evidence of EMT of
PMCs under pathologic conditions.
HMG-CoA reductase inhibitors, or statins, are potent inhibitors
of cholesterol biosynthesis and have emerged as the leading lipid-
lowering agents. However, it has been acknowledged that the
beneficial effects of statins are not mediated solely by their lipid-
lowering property, but also through distinct ‘‘pleiotropic’’ effects
[9–11]. In fact, statins exert these effects by preventing the
synthesis of other important isoprenoids of the cholesterol
biosynthetic pathway, such as FPP and GGPP that are
downstream of the mevalonate pathway [12]. These intermediates
play key roles in the post-translational modification of many
proteins, including small GTP binding proteins—the family of
Ras, Rho, Rap, and Rab GTPase—by serving as lipid attachments
through a process known as ‘‘prenylation’’ [13–15]. Isoprenylation
of these proteins permits the covalent attachment, subcellular
localization, and intracellular trafficking of membrane-associated
proteins [13–15]. Therefore, small G proteins are anchored to the
cell membrane if they are prenylated, while they remain in the
cytoplasm when prenylation is inhibited. In general, modification
of FPP is necessary for localization of Ras, whereas GGPP is
required for Rho, Rap, and Rab family proteins [12]. By
inhibiting the synthesis of mevalonate products, statins prevent
isoprenylation of small GTPases, leading to suppression of these
signal molecules [14]. To support this notion, we clearly
demonstrated that the expression of RhoA and Rac1 protein in
Figure 8. Immunohistochemical staining of the peritoneum of control (C), C+ simvastatin (C + statin), 4.25% PDF instillation (PD), or
4.25% PDF + simvastatin (PD + statin) rats. The intensity of E-cadherin staining was significantly lower, while Snail, a-SMA, and fibronectin
staining intensities were significantly higher in PD rats compared to C rats, and simvastatin significantly ameliorated these changes in PD rats (6200).
doi:10.1371/journal.pone.0109628.g008
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the membrane fraction was increased in cultured HPMCs exposed
to HG, and these increases were ameliorated by statin treatment.
In addition to the pivotal role of small RhoGTPases in the
regulation of cell shape, adhesion, migration, secretion, and
proliferation [12–14], several recent studies have found that small
RhoGTPases such as RhoA, Rac1, and Cdc42 exert a direct effect
on EMT in a number of cell types including renal [16–20], lens
[32], bronchial [33], and mammary epithelial cells [34].
Bhowmick et al. [34] showed that a RhoA-dependent mechanism
was responsible for TGF-b1-induced mammary epithelial EMT.
Moreover, some investigators demonstrated that overexpression of
active RhoA reduced E-cadherin expression and increased
mesenchymal cell markers [16], while transfection of a RhoA
dominant-negative vector or ROCK inhibition with Y-27632 or
fasudil inhibited EMT provoked by angiotensin II in renal tubular
epithelial cells [19]. This indicates that RhoA may be directly
involved in renal tubular epithelial EMT. Furthermore, in contrast
to the putative roles of Rac1 and Cdc42, which are believed to be
involved in the establishment and maintenance of epithelial
intercellular adhesions [35–37], activation of these proteins can
also induce EMT accompanied by breakdown of cell-cell adhesion
and rearrangement of the actin cytoskeleton [38–40]. Similar to
these cells, EMT-like changes caused by small GTPases can occur
in PMCs. A recent study by Zhang et al. [20] found that activation
of RhoA in rat PMCs by TGF-b1 up-regulated a-SMA, vimentin,
and collagen expression and down-regulated E-cadherin expres-
sion, suggesting that the RhoA/ROCK signaling pathway
mediated EMT in rat PMCs in response to TGF-b1. Based on
these findings, it is surmised that small GTPases such as RhoA,
Cdc42, and Rac1 may be involved in EMT.
Because statins have an inhibitory effect on the synthesis of
isoprenoid intermediates, it can be presumed that statins may
reverse EMT-like changes through inhibiting isoprenylation of
small RhoGTPases. This assumption was verified in the current
study. We showed for the first time that statin treatment
attenuated HG- or PD-induced EMT and ECM accumulation
in HPMCs in vitro and in vivo. In addition, we provided an
underlying mechanism of the effect of statins against EMT. The
present study revealed that HG increased membrane translocation
of RhoA and Rac1 and enhanced Rho-kinase activity in cultured
HPMCs. Moreover, HG-induced changes in EMT markers were
reversed by Rho and Rac inhibitors. Taken together, the results
suggest that HG increased isoprenylation of small GTPases, and
these proteins play a role in HG-induced EMT of HPMCs.
Furthermore, GGPP-treated HPMCs lost epithelial markers and
acquired mesenchymal markers, indicating that isoprenoid inter-
mediates were directly involved in EMT of HPMCs. All these
findings support evidence that statins can inhibit HG-induced
EMT in HPMCs, at least in part, through inhibiting isoprenyla-
tion and subsequently inactivating RhoA and Rac1.
Even though this study underscores an important role of statins
in terms of inhibiting small GTPases, it is possible that statins may
exhibit this favorable effect via other mechanisms. In fact, EMT
can be induced by a variety of cytokines or growth factors
including TGF-b [30], angiotensin II [41], fibroblast growth
factor-2 [42], epidermal growth factor [43], and platelet-derived
growth factor [44]. Furthermore, it can be triggered by
inflammation or oxidative stress [45], and statins have been
reported to abrogate some of these stimuli such as inflammation,
oxidative stress [46–48], connective tissue growth factor [49], or
TGF-b [50]. However, there is a lack of evidence supporting a role
for statins in inhibiting EMT by reducing these triggering factors.
On the other hand, our in vivo experiment demonstrated that
alteration of EMT markers and increased ECM accumulation in a
PD rat model were not completely ameliorated by statin
treatment. Based on these findings, it is implied that peritoneal
EMT is a complex process which is engaged by a wide spectrum of
factors other than RhoA and Rac1 activation. Therefore, the
results of the current study should be interpreted with caution, but
provide another potential mechanism of the pleiotropic effects of
statins with respect to inhibiting EMT. Finally, it is possible that
beneficial effect of statins is mediated through its fibrinolytic
activity [51,52]. Therefore, we measured tissue-type plasminogen
activator (t-PA) concentration in cell-conditioned media by ELISA
and determined plasminogen activator inhibitor-1 (PAI-1) expres-
sion by Western blot analysis. Interestingly, t-PA level was
significantly increased in HG-treated cell media compared to
controls, which was not altered by statin treatment. On the other
hand, PAI-1 expression was significantly increased in HG-treated
cells, while statin treatment decreased the increased expression of
PAI-1 in these cells (data not shown). Although t-PA has been
shown to play a role in fibrinolysis, it is reported to destruct tubule-
epithelial basement membrane, which promotes EMT [53]. Thus,
the increased t-PA level by HG treatment can be interpreted as a
process of EMT. In fact, our finding is supported by several studies
suggesting increased t-PA level in HG-treated vascular endothelial
cells [54] and PDF-treated HPMCs [55]. Of note, we also found
that statin treatment did not further alter the increased t-PA level
in HG-treated cells. This finding is not consistent with previous
studies showing that statins increase t-PA activity [51,52] Such
discrepancy is likely due to differences in cell type, time of
simulation, dose, and type of statins. Nevertheless, PAI-1
expression was significantly decreased by statin treatment.
Although our finding cannot fully support fibrinolytic activity of
statin, it suggests that statins can maintain balance between t-PA
and PAI-1, thus resulting in collagen degradation. This finding
adds more strengths of statin in terms of preserving peritoneal
membrane in addition to attenuating EMT.
Figure 9. Masson’s trichrome staining of the peritoneum of
control (C), C+ simvastatin (C + statin), 4.25% PDF instillation
(PD), or 4.25% PDF + simvastatin (PD + statin) rats. Peritoneal
fibrosis assessed by Masson’s trichrome staining was significantly more
extensive in PD rats with 4.25% PDF than C rats, and these changes
were significantly attenuated by simvastatin treatment (6200).
doi:10.1371/journal.pone.0109628.g009
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In conclusion, the present study found that PD-related EMT
was mediated through isoprenylation and subsequently activation
of RhoA and Rac1 in mevalonate pathway and statin treatment
attenuated EMT changes in HG-stimulated HPMCs and 4.25%-
PDF-instilled PD rats. These findings suggest that statins may be a
promising therapeutic strategy for preservation of peritoneal
membrane integrity in long-term PD patients.
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